Russian FederationTuberculosis profile
Population  2014 143 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 16 (15–16) 11 (11–11)
Mortality (HIV+TB only) 1.1 (0.83–1.3) 0.73 (0.58–0.91)
Prevalence  (includes HIV+TB) 160 (70–270) 109 (49–192)
Incidence  (includes HIV+TB) 120 (110–130) 84 (76–93)
Incidence (HIV+TB only) 5.5 (4.5–6.6) 3.8 (3.1–4.6)
         
Case detection, all forms (%) 85 (77–94)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 19 (14–25) 49 (40–59)
MDR-TB cases among notified pulmonary
TB cases
15 000 (11 000–19 000) 24 000 (19 000–29 000)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 37 296   7 982
Pulmonary, clinically diagnosed 40 894   6 753
Extrapulmonary 8 763   652
       
Total new and relapse 102 340    
Previously treated, excluding relapses 33 828    
Total cases notified 136 168    
Among 102 340 new and relapse cases:
3 195 (3%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 31 250 (84%) 13 925 (28%) 45 175
Laboratory-confirmed RR-/MDR-TB cases     15 585
Patients started on MDR-TB treatment ***     21 904
TB/HIV 2014 Number (%)
TB patients with known HIV status 67 425  
HIV-positive TB patients 5 251  
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (68) 83 301
Previously treated cases, excluding relapse, registered in 2013 (39) 6 934
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (40) 16 021
XDR-TB cases started on second-line treatment in 2012 (26) 1 318
Laboratories 2014  
Smear (per 100 000 population) 3.7
Culture (per 5 million population) 14.1
Drug susceptibility testing (per 5 million population) 10.4
Sites performing Xpert MTB/RIF 96
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 1 894
% Funded domestically 100%
% Funded internationally <1%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-02 Data: www.who.int/tb/data